ArticleBioconjugate chemistry2024
Data-Driven Design of Novel Polymer Excipients for Pharmaceutical Amorphous Solid Dispersions.
Article in Bioconjugate chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Automated and High-Throughput Phase Separation Control for Supramolecular Polymer Blends Enabled by Machine Learning.JACS Au · 2026Article
- Automation-Assisted Photoinduced Atom Transfer Radical Polymerization.ACS polymers Au · 2026Article
- Active Tablet Coating with Amorphous Solid Dispersion of Ibuprofen-HPMCAS from Organic Solution.Pharmaceutics · 2025Article
- SAXS Assistant: Automated SAXS analysis for structural discovery in biologics and polymeric nanoparticles.Biophysical journal · 2025Article
- Recent Techniques to Improve Amorphous Dispersion Performance with Quality Design, Physicochemical Monitoring, Molecular Simulation, and Machine Learning.Pharmaceutics · 2025Review
- Emerging polymeric nanocarriers for mRNA and protein therapeutics: design, challenges, and clinical outlook.Nanomedicine (London, England) · 2025Review
- Autonomous Discovery of Functional Random Heteropolymer Blends through Evolutionary Formulation Optimization.Matter · 2025Article
- Calorimetric Monitoring of the Sub-TMolecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
About 90% of active pharmaceutical ingredients (APIs) in the oral drug delivery system pipeline have poor aqueous solubility and low bioavailability. To address this problem, amorphous solid dispersions (ASDs) embed hydrophobic APIs within polymer excipients to prevent drug crystallization, improve solubility, and increase bioavailability. There are a limited number of commercial polymer excipients, and the structure-function relationships which lead to successful ASD formulations are not well-documented. There are, however, certain solid-state ASD characteristics that inform ASD performance. One characteristic shared by successful ASDs is a high glass transition temperature (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.